Treatment of AIDS and HIV-related conditions - 2002: Antiretroviral therapy

Journal of the American Board of Family Practice

Volumn 15, Issue 4, 2002, Pages 319-331

  Goldschmidt, Ronald H ^a,b,c   Dong, Betty J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; FLUINDOSTATIN; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; LORAZEPAM; MEVINOLIN; MIDAZOLAM; NELFINAVIR; NEVIRAPINE; PARACETAMOL; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SILDENAFIL; SIMVASTATIN; STAVUDINE; TEMAZEPAM; TENOFOVIR DISOPROXIL; TRIAZOLAM; UNINDEXED DRUG; VIDEX EC; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ANOREXIA; ANTIMICROBIAL THERAPY; ANXIETY DISORDER; APHTHOUS ULCER; ARTICLE; ASTHENIA; CARDIOMYOPATHY; COUGHING; DIARRHEA; ESOPHAGUS ULCER; FATIGUE; FEVER; FLU LIKE SYNDROME; GENERAL PRACTITIONER; GRANULOCYTOPENIA; HEADACHE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMYLASEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERSENSITIVITY REACTION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; INSOMNIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; MALAISE; MEGALOCYTOSIS; MENTAL DISEASE; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; OSTEOPENIA; OSTEOPOROSIS; PANCREATITIS; PANIC; PARONYCHIA; PERIPHERAL NEUROPATHY; PHARYNGITIS; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; RASH; RETINA DISEASE; SEIZURE; SKIN DISCOLORATION; STOMATITIS; THROMBOCYTOPENIA; VOMITING; ANTIBIOTIC RESISTANCE; DRUG ADMINISTRATION; DRUG COMBINATION; PRIMARY HEALTH CARE; STANDARD; UNITED STATES;

ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; PRACTICE GUIDELINES; PRIMARY HEALTH CARE; UNITED STATES;

EID: 0036637092     PISSN: 08938652     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Goldschmidt RH, Dong BJ. Treatment of AIDS and HIV-related conditions-2001. J Am Board Fam Pract 2001;14:283-309.
2. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Panel on Clinical Practices for Treatment of HIV Infection. The Living Document, February 4, 2002. Available at http://www.hivatis.org/trtgdlns.html. Accessed May 10, 2002.
3. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. US Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). USPHS/IDSA Prevention of Opportunistic Infections Working Group. November 28, 2001. Available at http://www.hivatis.org/oi_ guidelines.html. Accessed May 10, 2002.
4. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47(RR-20):1-58. Available at http://www.hivatis.org. Accessed May 10, 2002.
5. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Perinatal HIV Guidelines Working Group. Public Health Service. February 4, 2002. Available at http://www.hivatis.org/per_guidelines.html. Accessed May 10, 2002.
6. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. December 14, 2001. Available at http://www.hivatis.org/ped_guidelines.html. Accessed May 10, 2002.
7. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47(RR-7):1-33. Available at http://www.hivatis.org/hcare_guidelines.html. Accessed May 10, 2002.
8. Management of possible sexual, injecting-drug-use, or other nonoccupational exposure to HIV, including considerations related to antiretroviral therapy. Public Health Service statement. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47(RR-17):1-14. Available at http://www. hivatis.org/ne_guideline.html. Accessed May 10, 2002.
9. Phillips AN, Staszewski S, Weber R, et al, for the Swiss HIV Cohort Study Group, the Frankfurt HIV Clinic Study Group, and the EuroSIDA Study Group. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001;286:2560-7.
10. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286:2568-77.
11. Pomerantz RJ. Initiating antiretroviral therapy during HIV infection: confusion and clarity. JAMA 2001;286:2597-9.
12. Wanke CA, Falutz JM, Shevitz A, Phair JP, Kotler DP. Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus. Clin Infect Dis 2002;34:248-59.
13. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-30.
14. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001;344:984-96.